| Features: polyphenol |
| Found in red grapes and products made with grapes. Resveratrol is a polyphenol compound found in various plant species, including grapes, berries, and peanuts. • Anti-inflammatory effects, Antioxidant effects: - Antiplatelet aggregation for stroke prevention - BioAvialability use piperine - some sources may use Japanese knotweed roots (Reynoutria Japonica - root) as source which might contain Emodin (laxative) -known as Nrf2 activator, both in cancer and normal cells. Which raises controversity of use in ROS↑ therapies. Interestingly there are reports of NRF2↑ and ROS↑ in cancer cells. This raises the question of if it is a chemosensitizer. However other reports indicate NRF2 droping with Res, indicating it maybe a chemosenstizer. - RES is also considered to be them most effective natural SIRT1↑ -activating compound (STACs). However, in the presence of certain metals, such as copper or iron, resveratrol can undergo a process called Fenton reaction, which can lead to the generation of reactive oxygen species (ROS). The pro-oxidant effects of resveratrol are often observed at high concentrations, typically above 50-100 μM, and in the presence of certain metals or other pro-oxidant agents. In contrast, the antioxidant effects of resveratrol are typically observed at lower concentrations, typically below 10-20 μM. Clinical trials have used doses ranging from 150 mg to 5 grams per day. Lower doses (< 1 g/day) are often well-tolerated, but higher doses might be necessary for therapeutic effects and can be associated with side effects. -Note half-life 1-3 hrs?. BioAv poor: min 5uM/L required for chemopreventive effects, but 25mg Oral only yeilds 20nM. co-administration of piperine Pathways: - usually induce ROS production in cancer cells, while reducing ROS in normal cells. - ROS↑ related: MMP↓(ΔΨm), ER Stress↑, UPR↑, GRP78↑, Ca+2↑, Cyt‑c↑, Caspases↑, DNA damage↑, cl-PARP↑, HSP↓, - Lowers AntiOxidant defense in Cancer Cells: NRF2(typically increased), TrxR↓**, SOD↓, GSH↓ Catalase↓ HO1↓(wrong direction), GPx↓ - Raises AntiOxidant defense in Normal Cells: ROS↓, NRF2↑, SOD↑, GSH↑, Catalase↑, - lowers Inflammation : NF-kB↓, COX2↓, p38↓, Pro-Inflammatory Cytokines : NLRP3↓, IL-1β↓, TNF-α↓, IL-6↓, IL-8↓ - inhibit Growth/Metastases : TumMeta↓, TumCG↓, EMT↓, MMPs↓, MMP2↓, MMP9↓, TIMP2, IGF-1↓, uPA↓, VEGF↓, ROCK1↓, FAK↓, RhoA↓, NF-κB↓, CXCR4↓, SDF1↓, TGF-β↓, α-SMA↓, ERK↓ - reactivate genes thereby inhibiting cancer cell growth : HDAC↓, EZH2↓, P53↑, HSP↓, Sp proteins↓, - cause Cell cycle arrest : TumCCA↑, cyclin D1↓, cyclin E↓, CDK2↓, CDK4↓, CDK6↓, - inhibits Migration/Invasion : TumCMig↓, TumCI↓, TNF-α↓, FAK↓, ERK↓, EMT↓, TOP1↓, TET1↓, - inhibits glycolysis /Warburg Effect and ATP depletion : HIF-1α↓, PKM2↓, cMyc↓, GLUT1↓, LDH↓, LDHA↓, HK2↓, PFKs↓, PDKs↓, ECAR↓, OXPHOS↓, GRP78↑, Glucose↓, GlucoseCon↓ - inhibits angiogenesis↓ : VEGF↓, HIF-1α↓, Notch↓, FGF↓, PDGF↓, EGFR↓, Integrins↓, - inhibits Cancer Stem Cells : CSC↓, CK2↓, Hh↓, CD133↓, CD24↓, β-catenin↓, sox2↓, notch2↓, nestin↓, OCT4↓, - Others: PI3K↓, AKT↓, JAK↓, STAT↓, Wnt↓, β-catenin↓, AMPK, ERK↓, JNK, - Synergies: chemo-sensitization, chemoProtective, RadioSensitizer, RadioProtective, Others(review target notes), Neuroprotective, Cognitive, Renoprotection, Hepatoprotective, CardioProtective, - Selectivity: Cancer Cells vs Normal Cells |
| 2578- | ART/DHA, | RES, | Synergic effects of artemisinin and resveratrol in cancer cells |
| - | in-vitro, | Liver, | HepG2 | - | in-vitro, | Cerv, | HeLa |
| 3862- | CUR, | RES, | The metalloproteinase ADAM10: A useful therapeutic target? |
| - | Review, | AD, | NA |
| 1383- | CUR, | BBR, | RES, | Regulation of GSK-3 activity by curcumin, berberine and resveratrol: Potential effects on multiple diseases |
| - | Review, | NA, | NA |
| 3748- | CUR, | RES, | Hup, | Riv, | Gala | Natural acetylcholinesterase inhibitors: A multi-targeted therapeutic potential in Alzheimer's disease |
| - | Review, | AD, | NA |
| 872- | CUR, | RES, | New Insights into Curcumin- and Resveratrol-Mediated Anti-Cancer Effects |
| - | in-vitro, | BC, | TUBO | - | in-vitro, | BC, | SALTO |
| 128- | CUR, | RES, | Evaluation of biophysical as well as biochemical potential of curcumin and resveratrol during prostate cancer |
| - | in-vivo, | Pca, | NA |
| 134- | CUR, | RES, | MEL, | SIL, | Thioredoxin 1 modulates apoptosis induced by bioactive compounds in prostate cancer cells |
| - | in-vitro, | Pca, | LNCaP | - | in-vitro, | Pca, | PC3 |
| 182- | CUR, | RES, | GI, | Chemopreventive anti-inflammatory activities of curcumin and other phytochemicals mediated by MAP kinase phosphatase-5 in prostate cells |
| - | in-vitro, | Pca, | DU145 | - | in-vitro, | Pca, | PC3 | - | in-vitro, | Pca, | LNCaP | - | in-vitro, | Pca, | LAPC-4 |
| 685- | EGCG, | CUR, | SFN, | RES, | GEN | The “Big Five” Phytochemicals Targeting Cancer Stem Cells: Curcumin, EGCG, Sulforaphane, Resveratrol and Genistein |
| - | Analysis, | NA, | NA |
| 4664- | GEN, | CUR, | RES, | EGCG, | SFN | Targeting cancer stem cells by nutraceuticals for cancer therapy |
| - | Review, | Var, | NA |
| - | in-vitro, | Nor, | MCF10 | - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | MDA-MB-468 | - | in-vitro, | PC, | Bxpc-3 |
| - | in-vitro, | Pca, | PC3 | - | in-vitro, | Lung, | A549 | - | in-vitro, | Cerv, | HeLa | - | in-vitro, | BC, | MCF-7 | - | in-vitro, | Liver, | HepG2 |
| 4703- | PTS, | RES, | Pterostilbene and resveratrol: Exploring their protective mechanisms against skin photoaging - A scoping review |
| - | NA, | Nor, | NA |
| 4701- | PTS, | RES, | Targeting cancer stem cells and signaling pathways by resveratrol and pterostilbene |
| - | Review, | Var, | NA |
| 873- | QC, | RES, | CUR, | PI, | Combination Effects of Quercetin, Resveratrol and Curcumin on In Vitro Intestinal Absorption |
| - | in-vitro, | Nor, | NA |
| 67- | QC, | RES, | Overexpression of c-Jun induced by quercetin and resverol inhibits the expression and function of the androgen receptor in human prostate cancer cells |
| - | in-vitro, | Pca, | LNCaP | - | in-vitro, | Pca, | LAPC-4 |
| 3080- | RES, | Resveratrol: A miraculous natural compound for diseases treatment |
| - | Review, | Var, | NA |
| 3089- | RES, | The Role of Resveratrol in Cancer Therapy |
| - | Review, | Var, | NA |
| 3077- | RES, | Resveratrol attenuates matrix metalloproteinase-9 and -2-regulated differentiation of HTB94 chondrosarcoma cells through the p38 kinase and JNK pathways |
| - | in-vitro, | Chon, | HTB94 |
| 3078- | RES, | The Effects of Resveratrol on Prostate Cancer through Targeting the Tumor Microenvironment |
| - | Review, | Pca, | NA |
| 3088- | RES, | Notch signaling mediated repressive effects of resveratrol in inducing caspasedependent apoptosis in MCF-7 breast cancer cells |
| - | in-vitro, | BC, | MCF-7 |
| 3079- | RES, | Therapeutic role of resveratrol against hepatocellular carcinoma: A review on its molecular mechanisms of action |
| - | Review, | Var, | NA |
| 3086- | RES, | Resveratrol inhibits the tumor migration and invasion by upregulating TET1 and reducing TIMP2/3 methylation in prostate carcinoma cells |
| - | in-vitro, | Pca, | LNCaP | - | in-vitro, | Pca, | PC3 | - | in-vitro, | Pca, | DU145 |
| 3081- | RES, | Resveratrol and p53: How are they involved in CRC plasticity and apoptosis? |
| - | Review, | CRC, | NA |
| 3082- | RES, | Resveratrol Ameliorates the Malignant Progression of Pancreatic Cancer by Inhibiting Hypoxia-induced Pancreatic Stellate Cell Activation |
| - | in-vitro, | PC, | PANC1 | - | in-vitro, | PC, | MIA PaCa-2 | - | in-vivo, | NA, | NA |
| 3083- | RES, | Resveratrol suppresses breast cancer cell invasion by inactivating a RhoA/YAP signaling axis |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | MDA-MB-468 |
| 3084- | RES, | Resveratrol inhibits the proliferation of estrogen receptor-positive breast cancer cells by suppressing EZH2 through the modulation of ERK1/2 signaling |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | T47D |
| 3072- | RES, | Resveratrol ameliorates glioblastoma inflammatory response by reducing NLRP3 inflammasome activation through inhibition of the JAK2/STAT3 pathway |
| - | in-vitro, | GBM, | LN229 | - | in-vitro, | GBM, | U87MG |
| 3087- | RES, | Resveratrol cytotoxicity is energy-dependent |
| - | Review, | Var, | NA |
| 3085- | RES, | Resveratrol interrupts Wnt/β-catenin signalling in cervical cancer by activating ten-eleven translocation 5-methylcytosine dioxygenase 1 |
| - | in-vitro, | Cerv, | NA |
| 3067- | RES, | Proteomic Profiling Reveals That Resveratrol Inhibits HSP27 Expression and Sensitizes Breast Cancer Cells to Doxorubicin Therapy |
| - | in-vitro, | BC, | MCF-7 |
| 3059- | RES, | Resveratrol, an Nrf2 activator, ameliorates aging-related progressive renal injury |
| - | in-vivo, | Nor, | HK-2 |
| 3060- | RES, | Resveratrol targeting NRF2 disrupts the binding between KEAP1 and NRF2-DLG motif to ameliorate oxidative stress damage in mice pulmonary infection |
| - | in-vitro, | Nor, | RAW264.7 | - | in-vivo, | NA, | NA |
| 3061- | RES, | The Anticancer Effects of Resveratrol: Modulation of Transcription Factors |
| - | Review, | Var, | NA |